Abstract
Abstract Redox biocatalysis is currently gaining focus because it offers exquisite selectivity using mild oxidants, such as oxygen (which is environmentally benign). However, it is often challenging to implement oxidative reactions at scale due to the low activity and stability of the biocatalyst under industrial conditions. Consequently, it becomes critical to identify the bottlenecks for specific oxidation reactions as a first step in scale-up. Subsequently, we can identify where research the effort is required when developing a biocatalytic reaction for implementation in an industrial reaction, i.e., on biocatalyst development (e.g. improvement of expression levels), process development (e.g. improved oxygen supply, product removal strategies) or biocatalyst stabilization (e.g. through immobilization or directed evolution). This paper presents a systematic method to identify the bottleneck of a potential biocatalytic process using a monoamine oxidase to synthesize an intermediate in the manufacture of a drug for treating Hepatitis C (Telaprevir).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
